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Recombinant adeno-associated viral (rAAV) vectors have 
been widely used in pulmonary gene therapy research. In 
this study, we evaluated the transduction and expression 
efficiencies of several AAV serotypes and AAV2 capsid 
mutants with specific pulmonary targeting ligands in 
the mouse lung. The noninvasive intranasal delivery was 
compared with the traditional intratracheal lung delivery. 
The rAAV8 was the most efficient serotype at expressing 
α-1-antitrypsin (AAT) in the lung among all the tested 
serotypes and mutants. A dose of 1 × 1010 vg of rAAV8-
CB-AAT transduced a high percentage of cells in the 
lung when delivered intratrachealy. The serum and the 
broncho-alveolar lavage fluid (BALF) levels of human AAT 
(hAAT) were about 6- and 2.5-fold higher, respectively, 
than those of rAAV5 group. Among the rAAV2 capsid 
mutants, the rAAV2 capsid mutants that display a peptide 
sequence from hAAT (“long serpin”) indicated a twofold 
increase in transgene expression. For most vectors, the 
serum hAAT levels achieved after intranasal delivery were 
1/2 to 1/3 of those with the intratracheal method. Over-
all, rAAV8 was the most promising vector for the future 
application in gene therapy of pulmonary diseases such 
as AAT deficiency–related emphysema.
Received 18 January 2008; accepted 5 September 2008; published 
online 21 October 2008. doi:10.1038/mt.2008.217
IntroductIon
Recombinant adeno-associated virus (rAAV)-based vectors have 
been developed for a variety of pulmonary disorders including 
α-1-antitrypsin (AAT) deficiency and cystic fibrosis.1–4 However, 
the paucity of AAV2 receptors on the apical surface of airway epi-
thelium, the degradation of AAV in the cytoplasm, and the lack 
of integration of rAAV has limited its efficacy in clinical trials.5 
One potential solution to these problems is the use of  alternative 
AAV serotypes such as rAAV5, rAAV8, rAAV9, or AAV2 capsid 
mutants with specifically targeted ligands. These alternative 
capsids may bypass the binding and internalization barriers and 
achieve improved gene expression from a single administration. 
Recombinant AAV8 is emerging as a powerful gene therapy vector 
because of its ability to efficiently transduce many different tissues 
in vivo; however, studies demonstrating its affinity for lung gene 
transfer have not been performed. Interestingly, AAV8 shows high 
homology to rAAV9 which has been shown to transduce airways 
remarkably well.6 Both of theses serotypes have been implicated 
in binding the laminin receptor, which has been shown to be 
expressed in developing and adult lungs; thus, it is of great interest 
to determine whether rAAV8 also proves to be highly efficient at 
lung gene transfer.7–9
In an earlier work, we showed that two AAV2 capsid mutants 
with long and short serpin ligand insertions into the structural 
viral protein 1 at amino acid position 34 [VP1 (+34)] and VP2 
(+1) of the capsid increased the transduction efficiency for the 
human lung cell line IB3 by about 80- and 25-fold, respectively.10 
An other work has demonstrated that AAV2 capsid with an ApoE 
ligand in VP2 (+1) targeting the LDL receptor improved pancre-
atic islet transduction efficiency by 1.5-fold.4 Curiously, the LDL 
receptor has also been described to be present and upregulated 
in airway epithelial cells in response to viral  infection.11,12 This 
makes the ApoE mutant an attractive candidate for airway gene 
transfer along with AAV2 mutants incorporating the peptide 
THALWHT and serpin ligands which have also been reported 
to have high binding affinity to airway epithelial cells.13 To 
accomplish this, we inserted the ApoE, long serpin (LS), short 
serpin (SS), and THALWHT ligands into AAV capsid VP1(+34), 
VP2(+1), and VP3(+588) sites, which have been studied previ-
ously.10 We examined the mouse lung transduction character-
istics of these rAAV2 capsid mutants along with AAV5, AAV8, 
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and AAV9 pseudotypes. All vectors contained identical genomes 
with the AAV2 inverted terminal repeats flanking a transcrip-
tional unit composed of the chicken β-actin promoter cassette, 
the human AAT (hAAT) cDNA, and a poly A tail.5 The same 
vector genome was packaged into each different serotype or 
AAV2 capsid mutant so that any observed differences would be 
because of the capsid proteins themselves.
The purpose of our study was twofold: to compare (i) the lung 
transduction efficiency of various serotypes of AAV and AAV2 
capsid mutants with targeting ligands, and (ii) the efficiency of 
gene expression between the traditional intratracheal injection 
method with that of the noninvasive intranasal method.
results
Packaging of rAAV viruses
rAAV serotypes 2, 5, 8, 9, together with all AAV serotype 2 capsid 
mutants, were packaged under the same conditions. Among 12 
mutants, only 5 mutants could be successfully packaged and 
purified. The detailed titer information is shown in Table 1. 
The titer of AAV mutants A, B, and E was close to that of AAV2. 
The titer decreased by about tenfold in AAV mutants D and H. 
AAV mutants C, F, G, I, J, K, and L could not be successfully 
packaged.
hAAt expression in serum after in vivo transduction 
of the murine lung
To determine the transduction and AAT expression efficiency of 
the various viral vectors in vivo, serum samples from mice receiv-
ing the vectors either intranasally or intratrachealy were analyzed 
for levels of hAAT. The serum hAAT enzyme-linked immuno-
sorbent assay (ELISA) results are shown in Figure 1. The serum 
hAAT serum levels were stable for 4 months. Serum hAAT levels 
were highest in the AAV8 group, about five- to sevenfold higher 
than those of the AAV5 mice group. The serum levels were quite 
similar between the AAV5 and AAV9 groups although the AAV9 
group mice were injected only with 60% of virus dose compared 
with the other groups (Figures 1a,b, 4, and Table 2). Among 
AAV2 capsid mutants, both AAV long-serpin Mutants A and B 
increased serum hAAT level twofold higher than rAAV2, and 
AAV mutants D and H showed reduced efficiency in lung trans-
duction (Figure 1a,b and Table 2).
rAAV lung transduction efficiency among various 
serotypes and AAV 2 capsid mutants
Intratracheal doses of 1 × 1010 vector genomes of rAAV8 showed 
the highest expression in the lung compartment as determined 
by hAAT levels in the broncho-alveolar lavage fluid (BALF) and 
increased transduction over rAAV5 as shown in the analysis of 
 vector genomes (Figures 2 and 3). The BALF levels of hAAT were 
quite close among the AAV5, AAV8, and AAV9 pseudotypes after 
intranasal vector administration, whereas in the intratracheal 
groups, the hAAT levels of the rAAV8 group were 2.5-fold higher 
than those of AAV5 and AAV9 groups. AAV mutants A, B, and E 
increased the BALF levels of hAAT by two-, three-, and twofold, 
table 1 rAAV packaging titer
name Abbreviation titer (vg/ml)
AAV2/2-AAT AAV2 5.32 × 1012
AAV2-AAT-VP1-LS AAV-Mut A 7.58 × 1012
AAV2-AAT-VP2-LS AAV-Mut B 4.03 × 1012
AAV2-AAT-VP3-LS AAV-Mut C Undetectable
AAV2-AAT-VP1-SS AAV-Mut D 8.56 × 1011
AAV2-AAT-VP2-SS AAV-Mut E 3.12 × 1012
AAV2-AAT-VP3-SS AAV-Mut F Undetectable
AAV2-AAT-VP1-ApoE AAV-Mut G Undetectable
AAV2-AAT-VP2-ApoE AAV-Mut H 3.35 × 1011
AAV2-AAT-VP3-ApoE AAV-Mut I Undetectable
AAV2-AAT-VP1-THAL AAV-Mut J Undetectable
AAV2-AAT-VP2-THAL AAV-Mut K Undetectable
AAV2-AAT-VP3-THAL AAV-Mut L Undetectable
AAV2/5-AAT AAV-5 7.47 × 1013
AAV2/8-AAT AAV-8 8.93 × 1012
AAV2/9-AAT AAV-9 9.66 × 1010
The table shows the packaging titers of the various rAAVs. All of the rAAVs were 
packaged in the same way as described in Materials and Methods section.
AAT, α-1-antitrypsin; AAV, adeno-associated virus; rAAV, recombinant adeno-
associated virus.
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Figure 1 comparison of serum human α-1-antitrypsin (hAAt) lev-
els among the different recombinant adeno-associated viruses 
(rAAVs) and delivery routes. The blood of C57B16 mice receiving vari-
ous AAV serotypes or AAV2 capsid mutants intratrachealy or intranasally 
were collected every 4 weeks. The serum hAAT levels were assayed by 
enzyme-linked immunosorbent assay. (a) rAAVs delivered intratrachealy, 
(b) rAAVs delivered intranasally. Refer to table 2 for statistical analysis. 
Data are presented as group averages ± SEM (n = 5).
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respectively, compared to that of AAV 2 (Figure 2). The lung tissue 
real-time PCR results showed that in the AAV8 group, the trans-
duction efficiency was sixfold higher than that of AAV5 and 1.5-fold 
higher than that of rAAV9 (Figure 3) In addition, this is supported 
by the AAT immunostaining seen in the lungs (Figure 4).
comparison of rAAV lung transduction efficiency 
between intratracheal and intranasal delivery
The lung transduction efficiency was compared after intratra-
cheal versus intranasal delivery. For most of the rAAV vectors, the 
serum levels of hAAT after intranasal delivery were about 1/2 to 
1/3 of those with intratracheal injection (Figures 1, 4, and Table 2). 
Among the AAV2 capsid mutants, AAV mutant B was best after 
intratracheal delivery (Figure 1a), whereas AAV mutant A was best 
after intranasal delivery (Figure 1b). The BALF hAAT levels of the 
intranasal group reached about 1/3 to 1/5 of the intratracheal group 
(Figure 2). The lung tissue real-time PCR results showed that the 
CB-AAT DNA transfer efficiency in the intranasal group was about 
1/2 to 1/6 of the intratracheal group with the exception of AAV9, 
which had almost no difference between the two delivery methods 
(Figure 3).
safety of gene delivery
Bronchial epithelial hyperplasia was observed in two of five mice 
in the AAV mutant E intranasal delivery group (Figure 5a,b). 
Intraepithelial vesicles were also found in one mouse from this 
group (Figure 5c). Four of five mice in the AAV8 intratracheal 
delivery group demonstrated an increase in macrophage numbers 
(Figure 5d). No similar pathological changes were observed in 
negative control groups where phosphate buffered saline (PBS) 
was administrated intranasally or intratrachealy. The inflamma-
tion scores are shown (Figure 5a).
table 2 statistical analysis of serum hAAt levels
Intratracheal delivery Intranasal delivery
AAV8 versus AAV5 AAV8 versus AAV5
time difference (AAV8 > AAV5) P value time difference (AAV8 > AAV5) P value
4 27624 (±10420) 0.015* 4 7484 (±7176) 0.31
8 23872 (±5489) 0.0003* 8 6115 (±4486) 0.19
12 20121 (±3825) 0.0001* 12 4745 (±2141) 0.03*
16 16370 (±6341) 0.018* 16 3376 (±2802) 0.24
AAV8 versus AAV9 AAV8 versus AAV9
time difference (AAV8 > AAV9) P value time difference (AAV8 > AAV9) P value
4 26625 (±10354) 0.018* 4 11569 (±6841) 0.11
8 22617 (±5389) 0.0004* 8 8462 (±4262) 0.06
12 18609 (±3738) 0.0001* 12 5355 (±1909) 0.01*
16 14602 (±6249) 0.03* 16 2249 (±2278) 0.34
AAV2 versus MutA AAV2 versus MutA
time difference (AAV2 < MutA) P value time difference (AAV2 < MutA) P value
4 337 (±124) 0.013* 4 232 (±242) 0.35
8 323 (±95) 0.003* 8 313 (±127) 0.02*
12 309 (±131) 0.029* 12 393 (±99) 0.0008*
16 294 (200) 0.16 16 474 (±199) 0.027*
AAV2 versus MutB AAV2 versus MutB
time difference (AAV2 < MutB) P value time difference (AAV2 < MutB) P value
4 214 (±101) 0.05* 4 30 (±146) 0.84
8 303 (±64) 0.001* 8 70 (±118) 0.56
12 392 (±70) 0.0001* 12 111 (±105) 0.30
16 418 (±112) 0.008* 16 152 (±113) 0.20
AAV8 Intratracheal versus Intranasal
time difference (tracheal > nasal) P value
4 20,478 (±12883) 0.11
8 19,527(±6793) 0.009*
12 18,576(±3905) 0.0001*
16 17,624(±6346) 0.017*
The table shows the results for the growth curve models comparing different routes of administration and different serotypes. Comparisons were done at 4 weeks 
when AAT levels stabilized through week 16. The table shows the average differences of AAT levels for each comparison ± SD and their P value.
AAT, α-1-antitrypsin; AAV, adeno-associated virus.
*Statistically significant.
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dIscussIon
The lung is an important target for gene delivery because it offers 
an easily accessible large surface area and an extensive capillary 
network.14 When considering AAT deficiency, the lung intersti-
tium is thought to be the primary site of action for AAT to protect 
elastin and other extracellular matrix components. AAT levels in 
the interstitium are normally 2% of serum levels, as inactive AAT 
produced in the liver circulates in the blood and traffics into the 
lung components.15 Local AAV-mediated hAAT expression in 
alveolar cells may potentially circumvent this issue and produce a 
therapeutic effect without having to achieve high serum levels.16
rAAV has been used for gene transfer in the lung in preclini-
cal and clinical trials.5,17 One strategy for improving rAAV lung 
transduction efficiency would be to use a different capsid sero-
type or capsid mutants with a greater affinity for airway epithelial 
cells. Using different AAV capsids to deliver the same DNA cas-
sette, we compared the lung transduction efficiencies of the vari-
ous AAV capsids. Previous results from several groups showed that 
AAV8 virus is capable of conferring significantly higher levels of 
 hepatocyte,18 brain,19,20 and muscle transduction20 than other AAV 
serotypes. In view of these advantages, we tested the lung transduc-
tion efficiency of this serotype. Our results indicated that AAV8 
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Figure 4 Immunostaining for α-1-antitrypsin in the lung. Repre-
sentative lung histology sections images (×10 and ×20) of mice receiving 
1 × 1010 vg of various rAAV serotypes via both routes of administra-
tion. (a) rAAV2-intranasal, (b) rAAV5-intranasal, (c) rAAV8-intranasal, 
(d) rAAV9-intranasal, (e) rAAV2-intratracheal, (f) rAAV5-intratracheal, 
(g) rAAV8-intratracheal, (h) rAAV9-intratracheal.
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Figure 3 recombinant AAV genome copies in lung tissue. Four 
months after being injected with AAVs, animals were killed and lungs 
were collected and genomic DNA was extracted. Purified DNA was 
assayed by Taqman quantitative PCR for AAV copies. Data are presented 
as group averages ± SEM (n = 5).
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Figure 2 Human α-1-antitrypsin (hAAt) expression in broncho-
alveolar lavage fluid (BAlF). Four months after being injected with the 
rAAVs, animals were killed and their lungs were lavaged to measure hAAT 
levels present in the lung with an enzyme-linked immunosorbent assay. 
Data are presented as group averages ± SEM (n = 5).
table 3 Animal experimental plan
Group
Mice 
number Vector Abbreviation
AAV dosage 
(vg/mouse)
1 10 PBS
2 10 AAV2/2-AAT AAV2 1 × 1010
3 10 AAV2-AAT-VP1-LS AAV-Mut A 1 × 1010
4 10 AAV2-AAT-VP2-LS AAV-Mut B 1 × 1010
5 10 AAV2-AAT-VP1-SS AAV-Mut D 1 × 1010
6 10 AAV2-AAT-VP2-SS AAV-Mut E 1 × 1010
7 10 AAV2-AAT-VP2-ApoE AAV-Mut H 1 × 1010
8 10 AAV2/5-AAT AAV5 1 × 1010
9 10 AAV2/8-AAT AAV8 1 × 1010
10 10 AAV2/9-AAT AAV9 6 × 109
AAV vectors were administered into 10 groups of C57/Bl6 mice. Each mouse 
received either vector or PBS in a 30 μl volume injected intra-trachealy (5 mice/
group) or intra-nasally (5 mice/group).
AAT, α-1-antitrypsin; AAV, adeno-associated virus.
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was superior to AAV9, AAV5, AAV2, and AAV2 capsid mutants at 
expressing AAT in the murine lung. This result was confirmed by 
both vector-delivery methods and by hAAT levels in both serum 
and BALF. In addition, we confirmed earlier reports that show 
that lung transduction efficiency and subsequent AAT expression 
with AAV9 is superior to that of AAV5.21 However, Limberis et al.6 
reports a peak 60-fold difference in AAT serum levels between 
AAV5 and AAV9. Our results are not as striking; however, the 
dose used in our study is tenfold lower and thus it is possible that 
there may be a threshold of cells readily transducible with rAAV5 
at higher doses that may magnify this difference. Considering that 
only 6 × 109 vg (60% dosage of other AAV serotypes) was adminis-
trated in our experiment, the actual AAV9 transduction efficiency 
was an estimated to be twofold higher than that of AAV5. In con-
trast, the AAV2 capsid mutants demonstrated only very limited 
improvement of lung transduction with both delivery methods. 
These results suggest that newer AAV serotypes will be more prom-
ising than currently designed mutants for lung transduction.
After a single rAAV administration, the transgene expression 
was sustained for at least 4 months in both delivery methods. 
However, the hAAT in serum started to decrease after reaching a 
peak at 1 month after rAAV8 delivery. The rate decline was slow. 
Although the noninvasive intranasal delivery of rAAV is a very 
promising virus administration method which has been reported 
before, serum hAAT levels with intranasal delivery reached about 
1/2 to 1/3 of those with the intratracheal method, and the BALF 
levels of hAAT in the intranasal groups were about 1/3 to 1/5 of 
intratracheal groups. Our data demonstrated that the noninvasive 
intranasal delivery method is fairly efficient for gene transfer, but 
less efficient than intratracheal delivery. It is possible that AAT 
levels in the serum may not necessarily reflect levels of lung trans-
duction due to the use the ubiquitous chicken β-actin promoter 
and the relatively invasive nature of the intratracheal surgery. 
Certainly with a surgical delivery, some virus may accidentally 
end up transducing other tissues. Although this may explain some 
of the differences in serum levels between the two delivery routes, 
it is evident from BALF that AAT levels in the lung compartment 
are truly different between delivery routes.
In conclusion, we showed that AAV vectors packaged with 
the serotype 8 capsid resulted in the most robust AAT expression 
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Figure 5 Inflammatory changes after rAAV administration. (a) Pathological score of inflammation, 4 months after being injected with virus or PBS 
control, mice lungs were harvested and pathology scoring was done to evaluate the possible inflammation. (b) Hyperplasia in bronchial epithelial cells 
in mice receiving AAV mutant E mouse 4 months after intranasal delivery, the hyperplasia was found in the bronchial epithelial (×10). Macrophages 
are also observed in the region (arrows). (c) Vesicles in bronchial epithelial in AAV mutant E: mouse 4 months after intranasal delivery, the vesicles were 
found in the bronchial epithelial (×20), along with an occasional macrophage (arrows). (d) Macrophage infiltration and staining in rAAV8 transduced 
lung 4 months after intratracheal delivery. Data are presented as group averages (×40) (n = 5).
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in the mouse lung among all AAV serotypes tested. The serum 
transgene expression levels from the noninvasive intranasal 
delivery were within the same order of magnitude as those seen 
with the standard intratracheal delivery method; however, intra-
tracheal delivery resulted in significantly greater BALF expres-
sion of AAT among all serotypes tested. Furthermore, we showed 
even low doses (1010 vg) of rAAV8 via intratracheal delivery can 
successfully infect a high percentage of lung cells, resulting in 
long-term transgene expression. These results suggest that AAV8 
might have future applications in gene therapy for pulmonary 
diseases.
MAterIAls And MetHods
Construction of rAAV plasmids. The CB-AAT vector was described 
 previously.19 Briefly, it contains a CMV/chicken β-actin hybrid promoter, 
the hAAT cDNA, and poly A sequence. pDG-AAV2, pDG-AAV5, and 
pDG-AAV8 were used to pseudotype rAAV and have also been described 
 previously.6 pDG-AAV9 was cloned from a plasmid containing the AAV9 
capsid, which was a gift from the University of Pennsylvania.
pDG Vp1-LS, pDGVp2-LS, and pDG Vp3-LS were constructed 
by inserting 5′-aagtttaacaagccttttgtgttcctgatc-3′ long-serpin sequence 
between the Eag I site and the Mlu site of pDG-VP1(+34), pDG-VP2(+1), 
and pDG-VP3(+587), respectively.
pDG-Vp1-SS, pDG-Vp2-SS, and pDG Vp3-SS were constructed 
by inserting 5′-tttgtgttcctgatc-3′ small-serpin sequence into Eag I site 
and Mlu site of pDG-VP1(+34), pDG-VP2(+1), and pDG-VP3(+587), 
respectively.
pDG-Vp1-THALWHT, pDG-Vp2-THALWHT, and pDG-Vp3-
THALWHT were constructed by inserting 5′-acccacgcattatggcataca-3′ 
THALWHT sequence between the Eag I site and the Mlu site of pDG-
VP1(+34), pDG-VP2(+1), and pDG-VP3(+587), respectively.
pDG-Vp1-ApoE, pDG-Vp2-ApoE, and pDG-Vp3-ApoE were 
constructed by inserting 5′-ggcctgcgcaagctgcgcaagcgcctgctgcgcgactggctg 
aaggccttctacgacaaggtggccgaggacctggacgaggccttcggc-3′ ApoE ligand 
sequence between the Eag I site and the Mlu site of pDG-VP1(+34), pDG-
VP2(+1), and the pDG-VP3(+587), respectively.
Virus production and purification. The methods used for viral produc-
tion have been previously published.22 For the AAV2 vector and AAV2 
Vp1 and Vp2 mutants, the lysate was loaded immediately onto a HiTrap 
Heparin (Pharmacia) column and eluted with 1× PBS-MK containing 
0.5 mol/l NaCl. For rAAV5, rAAV8, rAAV9, and AAV2-Vp3 mutant, a 
HiTrap Q column (Amersham Pharmacia, Uppsala, Sweden) was used 
and fractions were eluted with 20 mmol/l Tris, 500 mmol/l NaCl (pH 8.5). 
The physical titers (in DNase-resistant particles) of the virus prepara-
tion were determined using DNA dot-blot hybridization. In a typical run 
of ten cell factories (2 × 109 cells), the packaging yields nearly 1 × 1013 
particles.19
Pulmonary delivery of rAAV-AAT vectors.
Intranasal vector delivery: Eight- to ten-week-old C57/Bl6 mice obtained 
from Jackson Laboratories were used for all experiments. The mice were 
anesthetized by inhaled isoflurane administered with oxygen using a pre-
cision vaporizer (induced at 3%, maintained at 1.5–3%) in a closed venti-
lation chamber and subsequently moved to the rodent surgery area where 
they were placed in a supine position and instilled with a 30-µl aliquot 
of virus. Both nostrils were instilled with 15 µl of virus or PBS. The mice 
were allowed to inhale the bolus naturally. Subsequently, the mice were 
monitored for respiratory distress.
Intratracheal vector injection: The ventral cervical region was clipped, 
and scrubbed with alternating iodine and alcohol wipes for 2 minutes. 
Adequacy of surgical anesthesia was assessed by withdrawal reflex 
secondary to pinching of the skin between toes, as well as monitoring 
for a rapid and steady respiratory effort. A 1% topical gel lidocaine was 
applied to the skin of the mouse before the incision, followed by gentle 
blunt separation of muscle bundles. Intratracheal vector injections were 
performed with a butterfly catheter (25 G); placement of the needle within 
the lumen of the trachea was confirmed by movement of the fluid column 
(within the clear tubing) with respiratory effort. Injection volume was a 
30-µl aliquot (1 × 1010 vg) of virus. The skin incision was then closed with 
a cyanoacrylate skin adhesive.
Ten groups of 10 mice received either intratracheal (n = 5) or intranasal 
(n = 5) injections in this portion of the study, as outlined in Table 3.
Collection of blood samples: Approximately 50–75 µl of serum was 
obtained from 100–150 µl of blood before viral (or control) delivery in 
all mice. Blood samples were collected every 4 weeks by cutting into the 
tail vein under 1.5–3.5% isoflurane anesthesia. A final blood sample was 
collected at the time of killing via cardiac puncture in all mice under 3.5% 
isoflurane anesthesia.
Ten groups of 12 mice received either intratracheal (n = 5) or intranasal 
(n = 5) injections in this portion of the study, as outlined in Table 3.
Necropsy, tissue harvest, and BALF collection: Animals were eutha-
nized by a 4% isoflurane induction followed by immediate cervical dis-
location. Lung tissue samples were obtained from one mouse in each 
group at 4 weeks after virus injection. After a broncho-alveolar lavage 
(BAL) was performed on the lungs, they were instilled with 4% para-
formaldehyde, then inflated and fixed with another 1 ml of 4% para-
formaldehyde. The lungs were then taken out of the thoracic cavity; 
upper lobes of the lung together with other organs were stored in 4% 
paraformaldehyde and used to make hematoxylin and eosin slides and 
paraffin-embedded slides. The rest of lung was stored in liquid nitrogen 
for real-time PCR analysis.
BAL: BAL was harvested at the time of killing in all mice. BAL was 
performed by cannulating the trachea in situ with a 22-G needle, instilling 
three aliquots (1.0 ml) of sterile PBS solution, and collecting the fluid by 
gentle aspiration. The total lavage fluid recovered from all animals was 
measured and stored at −80 °C until assayed by ELISA.
ELISA analysis.
Determination of serum AAT: The levels of hAAT were measured in the 
serum samples by ELISA as previously described in detail.18
Immunostaining for hAAT in mouse tissues: Paraformaldehyde-fixed 
paraffin-embedded tissue sections (4 µm) were sequentially deparaf-
finized, rehydrated, and blocked for endogenous peroxidase activity. 
After antigen retrieval in target retrieval solution (DakoCytomation, 
Carpinteria, CA), slides were serum blocked and incubated with either 
rabbit anti-hAAT (1:100; Research Diagnostic Institute, Flanders, NJ) 
or normal rabbit immunoglobulin as a negative control. Antibody bind-
ing was detected using the EnVision+ HRP kit (DakoCytomation) and 
DAB+ (DakoCytomation). Slides were counterstained using hematoxylin 
(Vector Labs, Burlingame, CA). The tissue images were captured using a 
Zeiss Axioskop equipped with an Axiocam camera.19
For determination of inflammatory cells, the tissue was stained with 
hematoxylin and eosin and slides were semi-quantitatively scored in a 
blinded fashion using the following scale: 0 = none, 1 = focal or 1–3 small 
foci of inflammation, 2 = moderately sized single lesion or multifocal 
small lesions, 3 = multifocal moderate to severe lesions, 4 = multifocal 
degeneration or necrosis.
Genomic DNA extraction and quantitative PCR: Extraction of genomic 
DNA was performed using the Qiagen DNAeasy Tissue Kit, and DNA con-
centrations (1:25) were determined. One microgram of DNA was used in all 
quantitative PCRs according to a previously used protocol in our lab,23 and 
reaction conditions followed those recommended by the manufacturer to 
include 45 cycles of 95 °C for 15 seconds, 60 °C for 1 minute. Primer pairs were 
designed for the CMV enhancer/chicken B-actin promoter as described, and 
a standard curve was established using the pCBAT plasmid.23
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Statistical analysis. Tests to examine differences in the serum levels of 
AAT between vector serotypes and mutants or delivery routes were based 
on growth curve models in which serum baseline levels and change over 
time were considered random effects and viral vector, delivery route, time 
and the interaction of these variables were fixed effects. Timepoints 4, 8, 
12, and 16 were coded in separate models as 0 to contrast the difference 
between levels of AAT outcomes. An unstructured covariance structure 
was used. Goodness of fit was assessed using Akaike’s information cri-
terion. We assumed a linear trend model that provided a better fit than 
curvilinear models.
When comparing BAL levels, two-tailed Student’s t-tests were used 
for determining statistical significance. Results are presented as group 
averages ± SEM and are considered significant when P < 0.05.
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